Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Novartis prepares novel HDAC4 inhibitors

June 21, 2013

FDA issues drug safety communication for Zyprexa Relprevv

June 20, 2013

Researchers at Roche disclose new LRRK2 inhibitors

June 20, 2013

Sarepta Therapeutics reports updated 84-week data from phase IIb eteplirsen study

June 20, 2013

FDA accepts RHB-103 NDA for review

June 20, 2013

Oxygen Biotherapeutics gives update on Oxycyte

June 19, 2013

ViroMed advances in phase II trial of VM-202-DPN

June 19, 2013

Civitas Therapeutics receives second Michael J. Fox Foundation grant for CVT-301

June 19, 2013

Fluvoxamine maleate enters Japanese phase III trial for pediatric OCD

June 19, 2013

New results reported in murine model of spinocerebellar ataxia

June 19, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...